Clinical Trial Update: Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 [Phase 1]

View source ↗

Summary

Phase 1 study of VES001 in asymptomatic GRN-FTD patients evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Frontotemporal Dementia

Drugs mentioned

• VES001

Snippet

Sponsor: Mads Kjolby | Conditions: Dementia, Frontotemporal Dementia | Phase 1 | Status: COMPLETED